Industry Newscrispr cas9gene therapycrispr therapeuticsbiotech investing
Analysts Update CRISPR Therapeutics Price Targets
6.1
Brokerages updated CRISPR Therapeutics' price targets in mid-February: Morgan Stanley on Feb. 17 raised its target to $33 from $32 but kept an Underweight rating; JPMorgan on Feb. 16 cut its target to $67 from $69 while maintaining Overweight; and Citi on Feb. 16 raised its target to $80, reaffirming Buy after Casgevy sales topped estimates. These moves reflect revenue beats and anticipated 2026 pipeline catalysts.
Key Points
- 1Analysts adjust CRSP price targets: Morgan Stanley $33, JPMorgan $67, Citi $80
- 2Cite Casgevy sales beat and upcoming 2026 clinical updates as drivers of valuation revisions
- 3Signal investors monitor 2026 pipeline releases; analyst ratings and CRSP share volatility may shift
Scoring Rationale
Broker price-target revisions and Casgevy sales provide actionable investor signals, but company-specific biotech news limits broader relevance.
Sources
Public references used for this report.
Practice with real FinTech & Trading data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
Active Verified Users by Income TierEasyTechnology Stocks with High BetaMediumPortfolio Performance ScorecardHard
250 free problems · No credit card
See all FinTech & Trading problems
